IPH 2101

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Human monoclonal antibody that blocks the interaction of KIR inhibitory receptors on NK (natural killer) cells with their ligands. It is hypothesized that by blocking these inhibitory signals, there will be enhanced activation of NK cells and tumor cell destruction.[1][2]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.

Patient drug information

No information available.


  1. Innate Pharma's IPH 2101 (Anti-KIR) site
  2. Information from Innate Pharma about monoclonal antibodies targeting NK cells